These findings are supported by earlier studies linking metabolic regulators like FDX1 to favorable outcomes in other malignancies, possibly due to their role in maintaining cellular redox balance and limiting aggressive tumor phenotypes [38, 39]. The gene discussed is FDX1; the disease is neoplasm.